These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 8886684)

  • 21. Fetomaternal alloimmune thrombocytopenia.
    Ahya R; Turner ML; Urbaniak SJ;
    Transfus Apher Sci; 2001 Oct; 25(2):139-45. PubMed ID: 11761276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis.
    Paidas MJ; Berkowitz RL; Lynch L; Lockwood CJ; Lapinski R; McFarland JG; Bussel JB
    Am J Obstet Gynecol; 1995 Feb; 172(2 Pt 1):475-9. PubMed ID: 7856672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experiences with fetomaternal alloimmune thrombocytopenia at a Swedish hospital over a 10-year period.
    Tiblad E; Olsson I; Petersson K; Shanwell A; Winiarski J; Wolff K; Westgren M
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):803-6. PubMed ID: 12911440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct fetal administration of immunoglobulins: another disappointing therapy in alloimmune thrombocytopenia.
    Weiner E; Zosmer N; Bajoria R; Sepulveda W; Vaughan JI; Letsky EA; Fisk NM
    Fetal Diagn Ther; 1994; 9(3):159-64. PubMed ID: 8060511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prenatal management of fetuses with alloimmune thrombocytopenia].
    Kroll H; Kiefel V; Giers G; Kaplan C; Murphy M; Waters A; Mueller-Eckhardt C
    Beitr Infusionsther Transfusionsmed; 1996; 33():150-5. PubMed ID: 8974688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neonatal alloimmune thrombocytopenia. A case report and a review of the literature.
    Lee A; Permezel M; Dennington P; Duke T; Doyle L; Robinson H
    Aust N Z J Obstet Gynaecol; 1993 Nov; 33(4):420-3. PubMed ID: 8179559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune thrombocytopenia in the foetus and the newborn: diagnosis and therapy.
    Kaplan C
    Transfus Clin Biol; 2001 Jun; 8(3):311-4. PubMed ID: 11499984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antenatal interventions for fetomaternal alloimmune thrombocytopenia.
    Rayment R; Brunskill SJ; Soothill PW; Roberts DJ; Bussel JB; Murphy MF
    Cochrane Database Syst Rev; 2011 May; (5):CD004226. PubMed ID: 21563140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT): Scientific Impact Paper No. 61.
    Regan F; Lees CC; Jones B; Nicolaides KH; Wimalasundera RC; Mijovic A;
    BJOG; 2019 Sep; 126(10):e173-e185. PubMed ID: 30968555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alloimmune thrombocytopenia.
    Skupski DW; Bussel JB
    Clin Obstet Gynecol; 1999 Jun; 42(2):335-48. PubMed ID: 10370852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-HPA-9bw (Maxa) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families.
    Kaplan C; Porcelijn L; Vanlieferinghen P; Julien E; Bianchi F; Martageix C; Bertrand G; Jallu V
    Transfusion; 2005 Nov; 45(11):1799-803. PubMed ID: 16271107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-invasive risk-assessment and bleeding prophylaxis with IVIG in pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia: management to minimize adverse events.
    Wienzek-Lischka S; Sawazki A; Ehrhardt H; Sachs UJ; Axt-Fliedner R; Bein G
    Arch Gynecol Obstet; 2020 Aug; 302(2):355-363. PubMed ID: 32495019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.
    Ghevaert C; Campbell K; Walton J; Smith GA; Allen D; Williamson LM; Ouwehand WH; Ranasinghe E
    Transfusion; 2007 May; 47(5):901-10. PubMed ID: 17465957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin.
    Bussel JB; Berkowitz RL; Lynch L; Lesser ML; Paidas MJ; Huang CL; McFarland JG
    Am J Obstet Gynecol; 1996 May; 174(5):1414-23. PubMed ID: 9065105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost effectiveness of empiric intravenous immunoglobulin for the antepartum treatment of fetal and neonatal alloimmune thrombocytopenia.
    Thung SF; Grobman WA
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1094-9. PubMed ID: 16157118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Three special cases of pregnancy outcome to reflect about].
    Lindemann R; Svenningsen L; Kjeldsen-Kragh J; Stiris TA; Killie MK; Husebekk A
    Tidsskr Nor Laegeforen; 2004 Sep; 124(17):2244-6. PubMed ID: 15457611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antenatal invasive and noninvasive management of alloimmune thrombocytopenia.
    Kornfeld I; Wilson RD; Ballem P; Wittmann BK; Farquharson DF
    Fetal Diagn Ther; 1996; 11(3):210-7. PubMed ID: 8739589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prenatal management of fetal alloimmune thrombocytopenia.
    Vox Sang; 1993; 65(3):180-9. PubMed ID: 8249359
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapy with intravenous immunoglobulin G (ivIgG) during pregnancy for fetal alloimmune (HPA-1a(Zwa)) thrombocytopenic purpura.
    Giers G; Hoch J; Bauer H; Bald R; Kiefel V; Kroll H; Hansmann M; Hanfland P; Mueller-Eckhardt C; Scharf RE
    Prenat Diagn; 1996 Jun; 16(6):495-502. PubMed ID: 8809890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuing controversy in alloimmune thrombocytopenia: fetal hyperimmunoglobulinemia fails to prevent thrombocytopenia.
    Nicolini U; Tannirandorn Y; Gonzalez P; Fisk NM; Beacham J; Letsky EA; Rodeck CH
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1144-6. PubMed ID: 2220919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.